MG
PRME icon

Michael Gelband’s Prime Medicine PRME Stock Holding History

Michael Gelband’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$437K Buy
+118,464
New +$393K ﹤0.01% 1270
2025
Q4 		– Sell
-33,494
Closed -$186K – 1958
2025
Q3 		$186K Buy
+33,494
New +$136K ﹤0.01% 1396
2025
Q1 		– Sell
-131,732
Closed -$385K – 1892
2024
Q4 		$385K Buy
+131,732
New +$462K ﹤0.01% 1218

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Michael Gelband's PRME Position: Q2 2026 in Review

Michael Gelband opened a new position in Prime Medicine (PRME) in Q2 2026: 118,464 shares worth $437K. The stake represents ﹤0.01% of the portfolio and ranks #1270 among its holdings. This is a return to the name: Michael Gelband previously reported a position in PRME as recently as Q3 2025.

Michael Gelband first reported a position in PRME in Q4 2024 and has held it in 3 quarters since. 186 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Michael Gelband held 118,464 shares of Prime Medicine worth $437K as of Q2 2026.
  • Prime Medicine was a new Michael Gelband position in Q2 2026.
  • Prime Medicine made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1270 holding.
  • Michael Gelband first reported a position in Prime Medicine in Q4 2024 and has held it in 3 quarters since.
  • 186 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.